- INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC — Active Not Recruiting • Phase II / Phase III • Oncology • NCT06295731.
- Review the linked registry entry for study design, population, endpoints, and operational status.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
This seamless phase 2/3 randomized controlled study will evaluate the efficacy and safety of the hexavalent OX40 agonist antibody INBRX-106 combined with the anti-PD-1 antibody pembrolizumab versus pembrolizumab (+ placebo in phase 3) as first-line treatment for patients with locally advanced recurrent or metastatic head and neck squamous cell carcinoma (R/M HSNSCC) incurable by local therapies, expressing PD-L1 with a combined proportion score (CPS) ≥20. Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC) Interventions: INBRX-106, Pembrolizumab Lead Sponsor: Inhibrx Biosciences, Inc Planned Enrollment: 410 participants